KYMR Kymera Therapeutics Inc
Price (delayed)
$22.07
Market cap
$1.43B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
$1.4B
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein
Highlights
The equity has soared by 112% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's quick ratio has surged by 58% YoY but it has decreased by 13% QoQ
KYMR's net income has dropped by 52% year-on-year and by 34% since the previous quarter
KYMR's revenue is down by 46% from the previous quarter and by 40% YoY
Key stats
What are the main financial stats of KYMR
Market
Valuations
Earnings
Shares outstanding
64.94M
Market cap
$1.43B
Enterprise value
$1.4B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.71
Price to sales (P/S)
35.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.64
Revenue
$47.07M
Gross profit
$47.07M
Operating income
-$261.64M
Net income
-$223.86M
EBIT
-$223.61M
EBITDA
-$216.24M
Free cash flow
-$207.34M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.76
Book value per share
$12.9
Revenue per share
$0.63
TBVPS
$13.03
Total assets
$978.04M
Total liabilities
$142.42M
Debt
$87.76M
Equity
$835.62M
Working capital
$442.5M
Debt to equity
0.11
Current ratio
7.53
Quick ratio
7.3
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-459.4%
Gross margin
100%
Net margin
-475.6%
Operating margin
-555.8%
Return on assets
-24.2%
Return on equity
-28.7%
Return on invested capital
-26.4%
Return on capital employed
-24.6%
Return on sales
-475%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYMR stock price
How has the Kymera Therapeutics stock price performed over time
Intraday
-6.84%
1 week
-25.49%
1 month
-28.06%
1 year
-39.1%
YTD
-45.14%
QTD
-19.36%
Financial performance
How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$47.07M
Gross profit
$47.07M
Operating income
-$261.64M
Net income
-$223.86M
Gross margin
100%
Net margin
-475.6%
The operating margin has plunged by 164% YoY and by 143% from the previous quarter
KYMR's net margin has dropped by 154% year-on-year and by 149% since the previous quarter
The company's operating income has shrunk by 58% YoY and by 31% QoQ
KYMR's net income has dropped by 52% year-on-year and by 34% since the previous quarter
Growth
What is Kymera Therapeutics's growth rate over time
Valuation
What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
1.71
P/S
35.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.64
The company's EPS fell by 27% QoQ and by 18% YoY
The equity has soared by 112% YoY but it has contracted by 6% from the previous quarter
The stock's price to book (P/B) is 61% less than its 5-year quarterly average of 4.4 and 45% less than its last 4 quarters average of 3.1
KYMR's revenue is down by 46% from the previous quarter and by 40% YoY
The price to sales (P/S) is 15% lower than the last 4 quarters average of 41.4 but 8% higher than the 5-year quarterly average of 32.5
Efficiency
How efficient is Kymera Therapeutics business performance
The company's return on sales has shrunk by 154% YoY and by 149% QoQ
KYMR's return on assets is down by 19% since the previous quarter but it is up by 4.3% year-on-year
The company's return on equity rose by 18% YoY but it fell by 15% QoQ
The return on invested capital has declined by 17% since the previous quarter but it has grown by 8% year-on-year
Dividends
What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYMR.
Financial health
How did Kymera Therapeutics financials performed over time
The total assets has soared by 70% YoY but it has contracted by 5% from the previous quarter
The current ratio has surged by 59% year-on-year but it has declined by 12% since the previous quarter
KYMR's debt is 89% smaller than its equity
The equity has soared by 112% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's debt to equity has decreased by 48% YoY but it has increased by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.